Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Shukui Qin, MD; Feng Bi, MD; Shanzhi Gu, MD; Yuxian Bai, MD; Zhendong Chen, MD; Zishu Wang, MD; Jieer Ying, MD; Yinying Lu, MD; Zhiqiang Meng, MD; Jufeng Wang, MD; Liqing Wu, MD; Qiuhong Zheng, MD; Aibing Xu, MD; Chengxu Cui, BA; and Feng Chen, PhD

PURPOSE
Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study compared the efficacy and safety of donafenib versus sorafenib as first-line therapy for advanced HCC.

PATIENTS AND METHODS
This open-label, randomized, parallel-controlled, multicenter phase II-III trial enrolled patients with unresectable or metastatic HCC, a Child-Pugh score ≤7, and no prior systemic therapy from 37 sites across China. Patients were randomly assigned (1:1) to receive oral donafenib (0.2 g) or sorafenib (0.4 g) twice daily until intolerable toxicity or disease progression. The primary end point was overall survival (OS), tested for noninferiority and superiority. Efficacy was primarily assessed in the full analysis set (FAS), and safety was assessed in all treated patients.

RESULTS
Between March 21, 2016, and April 16, 2018, 668 patients (intention-to-treat) were randomly assigned to donafenib and sorafenib treatment arms; the FAS included 328 and 331 patients, respectively. Median OS was significantly longer with donafenib than sorafenib treatment (FAS; 12.1 v 10.3 months; hazard ratio, 0.831; 95% CI, 0.699 to 0.988; \( P = .0245 \)): donafenib also exhibited superior OS outcomes versus sorafenib in the intention-to-treat population. The median progression-free survival was 3.7 v 3.6 months (\( P = .0570 \)). The objective response rate was 4.6% v 2.7% (\( P = .2448 \)), and the disease control rate was 30.8% v 28.7% (FAS; \( P = .5532 \)). Drug-related grade ≥3 adverse events occurred in significantly fewer patients receiving donafenib than sorafenib (125 [38%] v 165 [50%]; \( P = .0018 \)).

CONCLUSION
Donafenib showed superiority over sorafenib in improving OS and has favorable safety and tolerability in Chinese patients with advanced HCC, showing promise as a potential first-line monotherapy for these patients.

J Clin Oncol 39:3002-3011. © 2021 by American Society of Clinical Oncology

INTRODUCTION
Liver cancer is one of the most common cancers worldwide and in China.1,2 China has the highest global incidence, accounting for more than half of the new cases and deaths caused by liver cancer in the world.1,2 Hepatocellular carcinoma (HCC) represents 90% of liver malignancies.3 Most patients are diagnosed at the advanced stage with a median survival of 6-8 months.3 The diagnosis and treatment of HCC is a major public health concern in China.4,5 In comparison with their Western counterparts, Chinese patients with HCC tend to be younger, have advanced-stage disease, and predominantly hepatitis B virus (HBV)-positive, resulting in poor prognosis.5,6 At present, only sorafenib, lenvatinib, and oxaliplatin-based systemic chemotherapy have been approved in China as first-line systemic treatment for advanced HCC.7,8 Sorafenib was the first molecular targeted agent approved for the treatment of unresectable or metastatic HCC and remains the standard first-line therapy.3,9 However, sorafenib is associated with several limitations in clinical practice. Sorafenib demonstrated the median overall survival (mOS) of 10.7-14.7 months in patients worldwide and 6.5-11.4 months in Chinese or Asian patients,10 with potential for improvement in overall survival (OS) outcomes. Nevertheless, over the past 13 years, no other monotherapy has significantly improved OS compared with sorafenib, although the
CONTEXT

Key Objective
Sorafenib is a standard first-line treatment for advanced hepatocellular carcinoma (HCC). To date, no monotherapy agent has shown superior overall survival (OS) outcomes in a head-to-head trial with sorafenib. Donafenib, a deuterated sorafenib derivative, exhibited an improved pharmacokinetic profile and favorable efficacy and safety in phase I studies. This phase II-III trial evaluated the efficacy and safety of first-line donafenib versus sorafenib in Chinese patients with advanced HCC.

Knowledge Generated
Compared with sorafenib, donafenib prolonged OS with statistical significance (hazard ratio, 0.83; \( P = .0245 \)), and the superiority criteria for OS were met. Donafenib also presented improved safety and tolerability; common drug-related adverse events like hand-foot skin reactions and diarrhea, as well as drug-related grade \( \geq 3 \) adverse events, occurred in fewer patients receiving donafenib than sorafenib.

Relevance
On the basis of these results, donafenib is likely to emerge as a new frontline standard for Chinese patients with advanced HCC; its safety and efficacy in other ethnic populations, and how it compares with other current systemic therapies for advanced HCC such as atezolizumab/bevacizumab, will require further investigation.

METHODS

Study Design and Participants
This randomized, open-label, parallel-controlled phase II-III clinical trial was conducted in 37 clinical research centers across China. The study enrolled patients who had unresectable or metastatic HCC, with diagnoses confirmed histopathologically, cytologically, or clinically (in accordance with the guidelines by the Chinese Ministry of Health, which are aligned with the international diagnostic criteria for HCC).\(^22,23\) Enrolled patients had \( \geq 1 \) measurable lesion, as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), a Child-Pugh liver function score \( \leq 7 \), an Eastern Cooperative Oncology Group performance score 0-1, and were HCC systemic therapy-naive. Full inclusion and exclusion criteria are included in the trial Protocol (online only).

The study Protocol was approved by the ethics committees of all participating centers. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki, ICH Good Clinical Practice E6, and local laws and regulations. All patients provided written informed consent.

Study Treatment and Assessments
Eligible patients were randomly assigned 1:1 to receive oral donafenib (0.2 g twice a day) and sorafenib (0.4 g twice a day). Factors used in stratified random assignment included alpha-fetoprotein (AFP, \( < 400 \mu g/L \) \( \geq 400 \mu g/L \)), history of locoregional HCC therapy (yes \( v \) no), Barcelona Clinic Liver Cancer (BCLC) stage (B \( v \) C), and portal vein invasion and/or extrahepatic metastases (present \( v \) absent). Treatment continued until the incidence of progressive disease (PD; as per RECIST 1.1), occurrence of severe toxicity or intolerance, delay in treatment by \( > 2 \) weeks, poor compliance, investigator’s decision because of new medical information, or pregnancy. A safety examination was performed once every 4 weeks, and an imaging evaluation once every 8 weeks. If the investigator considered a patient who developed radiologic PD but had good tolerance and showed evidence of clinical benefits (ie, obvious tumor necrosis, improved or stable quality of life, and relief of liver cancer–related symptoms), the patient could continue with study treatment after informed consent was obtained, until the criteria for treatment termination...
were met. In the event of grade 4 hematologic or grade 3 nonhematologic toxicities, according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0, study treatment interruptions and dose reductions were allowed until daily dose (to once daily and then further to once every other day) were allowed.

**Study End Points**

The primary end point was OS. Secondary end points included progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), disease control rate (DCR), survival rates at 6, 9, 12, and 18 months, and safety. PFS, TTP, ORR, and DCR were assessed by the investigator and Independent Review Committee (IRC) according to RECIST 1.1. The final analysis was based on assessment by IRC who were blinded to treatment identity. ORR and DCR were calculated according to confirmed responses (on the basis of two evaluations ≥ 8 weeks apart).

**Statistical Analysis**

The primary end point (OS) was first tested for non-inferiority; hierarchical testing for superiority would follow without multiple comparison adjustments if noninferiority was achieved. On the basis of the phase Ib donafenib study and the Asia-Pacific study of sorafenib, the assumed hazard ratio (HR) for OS was 0.85. The chosen noninferiority margin of 1.08 corresponds to 50% retention of sorafenib’s effect over placebo on the basis of the SHARP trial. This was deemed not clinically significant and approved by the China regulatory agency. It was estimated that 553 deaths would be required to have an 80% power to claim noninferiority at a significance level of 0.05 (two-sided). To observe the required number of deaths, a total of 660 patients were planned to be recruited.

An adaptive design was adopted for this phase II-III study. A total of 80 patients were to be enrolled in stage I (ie, phase II). The trial would continue to stage II if any of the following criteria were met: (1) At least 11 patients in the donafenib group achieved disease control (DCR ≥ 27.5%) without statistical difference between the two groups and (2) partial response (PR) was observed in two or more patients in the donafenib group. In stage II, an additional 580 patients would be recruited. The final analyses would be based on all 660 patients from the two stages.

mOS was calculated by the Kaplan-Meier method. OS comparison was performed using stratified log-rank test with random assignment stratification factors. HRs were estimated using Cox proportional hazards model, with treatment group and random assignment stratification factors as fixed effects and site as a random factor. Non-inferiority could be claimed if the upper limit of the 95% CI for HR was < 1.08; additionally, if this was < 1.00, superiority of donafenib over sorafenib for OS could be claimed. PFS and TTP were evaluated in the same way. Differences in ORR and DCR were analyzed using the Cochrane–Mantel–Haenszel test.

The primary efficacy analysis was based on the full analysis set (FAS, all randomly assigned patients without major eligibility violation who received ≥ 1 dose of study drug) and the per-protocol set (patients who completed ≥ 1 treatment course, with no major protocol deviation that might have affected efficacy evaluation). The intention-to-treat (ITT, all randomly assigned cases) population was used for supportive analysis. A prespecified subgroup analysis of OS was performed in the FAS. The safety analysis set included all treated patients. Statistical analysis was performed using SAS version 9.4. An independent third-party data monitoring committee (IDMC) was set up to monitor patients’ safety and the study progress.

**RESULTS**

Between March 21, 2016, and April 16, 2018, 1,075 patients were screened, of whom 668 were randomly assigned (ITT, 334 in each arm). By December 28, 2016, among the patients enrolled in stage I, five in the donafenib group had achieved PR confirmed by IRC; this met the criterion of continuing to stage II. The FAS consisted of 659 patients (donafenib, n = 328; sorafenib, n = 331). Six patients in the donafenib arm were excluded from the FAS: one did not receive the study drug and five did not meet major inclusion criteria, three of whom had prior systemic treatment and the other two had received liver transplantation. Three patients in the sorafenib arm were excluded from the FAS: two did not receive the study drug and one did not meet major inclusion criterion (history of liver transplantation). A total of 665 treated patients were included in the safety analysis set (donafenib, n = 333; sorafenib, n = 332). As of September 30, 2019, 642 (97%) of 665 patients had discontinued treatment, including 322 (97%) in the donafenib arm and 320 (96%) in the sorafenib arm (Fig 1). Discontinuation of treatment was mainly due to investigator-assessed PD.

Baseline characteristics were well-balanced between the treatment arms. Among the 659 patients in the FAS, 594 (90%) had HBV infection, 576 (87%) were BCLC stage C, 642 (97%) were Child-Pugh Class A (scores 5-6), 422 (64%) had an Eastern Cooperative Oncology Group performance score of 1, 350 (53%) had baseline AFP ≥ 400 µg/L, and 484 (73%) had portal vein invasion and/or extrahepatic metastases (Table 1).

**Efficacy**

In the FAS, donafenib was associated with a significantly longer mOS than sorafenib (12.1 v 10.3 months; HR, 0.831; 95% CI, 0.699 to 0.988; \( P = .0245 \); Fig 2A). The upper limit of 95% CI for HR was < 1.08 and < 1.00, indicating that both the noninferiority and superiority hypotheses hold true. The 18-month survival rate was higher with donafenib than sorafenib treatment (35.4% v 28.1%; \( P = .0460 \); Table 2). The OS results in the ITT were similar to those in the FAS, with mOS of 12.0 months and
10.1 months for the donafenib and sorafenib arms, respectively (HR, 0.839; 95% CI, 0.706 to 0.996; P = .0309; Fig 2B). Similar OS trends were observed in the per-protocol set (Appendix Fig A1, online only). In the FAS, a trend of superior OS benefit with donafenib versus sorafenib was consistently observed across most predefined subgroups and statistically significant improvement in OS was achieved in some subgroups (Appendix Fig A2, online only).

The median PFS (FAS) for donafenib versus sorafenib was 3.7 v 3.6 months (HR, 0.909; 95% CI, 0.763 to 1.082; P = .0570; Fig 2C), and the median TTP was 3.7 v 3.7 months (HR, 0.931; 95% CI, 0.777 to 1.117; P = .1029; Appendix Fig A3, online only). For best overall response, one patient (0.3%) achieved a complete response (CR) and 19 patients (5.8%) achieved PR in the donafenib arm, whereas no CR and 12 (3.6%) cases of PR were recorded with sorafenib treatment (Table 2). The ORRs were 4.6% and 2.7%, and the DCRs were 30.8% and 28.7%, in the donafenib and sorafenib arms, respectively. At week 24, a higher proportion of patients achieved disease control with donafenib (20.7%) than sorafenib (15.7%). Subsequent analyses confirmed that DCR at week 24 had a significant impact on long-term survival (P < .0001).

**Exposure and Safety**

In the safety analysis set, median exposure times were 110.0 days (interquartile range [IQR] 56.0-205.5 days) with donafenib and 113.0 days (IQR 56.0-213.0 days) with sorafenib treatment. Ninety-six patients (29%) in the donafenib arm and 127 (38%) in the sorafenib arm continued study drug administration for > 28 days after PD. Ninety patients (27%) in the donafenib arm and 111 (33%) in
| Characteristic                                      | Donafenib (n = 328) | Sorafenib (n = 331) | P      |
|---------------------------------------------------|---------------------|---------------------|--------|
| **Age, years**                                    |                     |                     | .5906  |
| Median (IQR)                                      | 53 (46-62)          | 53 (46-61)          |        |
| Sex                                               |                     |                     | .4217  |
| Male                                              | 281 (86)            | 291 (88)            |        |
| Female                                            | 47 (14)             | 40 (12)             |        |
| **BMI, kg/m²**                                    |                     |                     | .4400  |
| Median (IQR)                                      | 23 (21-25)          | 23 (21-25)          |        |
| **ECOG performance status**                       |                     |                     | .426   |
| 0                                                 | 127 (39)            | 110 (33)            |        |
| 1                                                 | 201 (61)            | 221 (67)            |        |
| **Time of HCC diagnosis, months**                 |                     |                     | .1514  |
| Median (IQR)                                      | 9 (2-27)            | 7 (2-19)            |        |
| **HCC etiology**                                 |                     |                     | .4746  |
| HBV                                               | 293 (89)            | 301 (91)            |        |
| HCV                                               | 7 (2)               | 5 (2)               |        |
| NAFLD                                             | 0                   | 2 (1)               |        |
| Others                                            | 28 (9)              | 23 (7)              |        |
| **BCLC staging**                                 |                     |                     | .8719  |
| B                                                 | 42 (13)             | 41 (12)             |        |
| C                                                 | 286 (87)            | 290 (88)            |        |
| **Child-Pugh score**                             |                     |                     | .4984  |
| 5                                                 | 262 (80)            | 259 (78)            |        |
| 6                                                 | 62 (19)             | 59 (18)             |        |
| 7                                                 | 4 (1)               | 13 (4)              |        |
| **Portal vein invasion and/or extrahepatic metastases** |                 |                     | 1.0000 |
| Absent                                           | 87 (27)             | 88 (27)             |        |
| Present                                           | 241 (73)            | 243 (73)            |        |
| **AFP, µg/L**                                     |                     |                     | .1629  |
| < 400                                             | 155 (47)            | 154 (47)            |        |
| ≥ 400                                             | 173 (53)            | 177 (53)            |        |
| Median (IQR)                                      | 208 (8-3,541)       | 210 (9-2,582)       |        |
| **Received previous locoregional therapy**        |                     |                     | .8481  |
| Yes                                               | 261 (80)            | 261 (79)            |        |
| No                                                | 67 (20)             | 70 (21)             |        |
| **Site of target lesions**                        |                     |                     | NA     |
| Liver                                             | 266 (81)            | 256 (77)            |        |
| Lung                                              | 80 (24)             | 73 (22)             |        |
| Lymph node                                        | 42 (13)             | 50 (15)             |        |
| No. of target lesions                             |                     |                     | .9955  |
| 1                                                 | 117 (36)            | 119 (36)            |        |
| 2                                                 | 143 (44)            | 146 (44)            |        |
| 3                                                 | 45 (14)             | 43 (13)             |        |
| ≥ 4                                               | 23 (7)              | 23 (7)              |        |

**NOTE.** Data are No. (%) unless otherwise indicated.

**Abbreviations:** AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; FAS, full analysis set; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IQR, interquartile range; NA, not applicable; NAFLD, nonalcoholic fatty liver disease.

*As per the Response Evaluation Criteria in Solid Tumors version 1.1.
the sorafenib arm had at least one dose interruption. Among patients with dose interruptions, 89 patients (99%) in the donafenib arm and 107 (96%) in the sorafenib arm resumed treatment. Dose reductions were applied for 76 (23%) donafenib-treated and 98 (30%) sorafenib-treated patients.

Adverse events (AEs) were reported by 332 (100%) and 329 (99%) patients in the donafenib and sorafenib arms, respectively, with 314 (94%) and 321 (97%) patients reporting drug-related AEs (Table 3). Six patients (2%) in the donafenib arm and 12 patients (4%) in the sorafenib arm reported AEs that resulted in death. Only two cases of fatal AEs (hepatic dysfunction and pulmonary infection), both in the sorafenib arm, were considered by investigators as possibly related to the investigational drug.

Fifty-five patients (17%) in the donafenib arm and 67 patients (20%) in the sorafenib arm reported at least one serious adverse event (SAE). Among these, 23 (7%) donafenib-treated and 22 (7%) sorafenib-treated patients reported drug-related SAEs. The most common drug-related SAEs were hepatic dysfunction (three [1%] donafenib-treated patients v seven [2%] sorafenib-treated patients), upper GI hemorrhage (three [1%] v four [1%]), and diarrhea (two [1%] v one [≤ 1%]).

The most common drug-related AEs were HFSR (168 patients [50%] in the donafenib arm v 222 [67%] in the sorafenib arm) and diarrhea (99 [30%] v 157 [47%]; Table 4). A total of 191 patients (57%) in the donafenib arm and 224 (67%) in the sorafenib arm experienced at least one grade ≥ 3 AE (P = .0082). In addition, the incidence of drug-related grade ≥ 3 AEs was significantly lower with donafenib than sorafenib treatment (125 [38%] v 165 [50%]; P = .0018; Table 3). Common grade ≥ 3 drug-related AEs included hypertension (30 [9%] v 29 [9%]), HFSR (19 [6%] v 41 [12%]), decreased platelet count (13 [4%] v 5 [2%]), hypophosphatemia (11 [3%] v 15 [5%]), elevated AST (eight [2%] v 16 [5%]), diarrhea (six [2%] v 11 [3%]), and elevated ALT (six [2%] v nine [3%]) (Table 4).

A total of 101 patients (30%) in the donafenib arm and 141 (42%) in the sorafenib arm experienced AEs leading to dose interruption and reduction (P = .0013), among which 84 (25%) and 120 (36%) were drug-related (P = .0025). The number of patients reporting AEs that resulted in treatment discontinuation was also lower with donafenib than sorafenib (34 [10%] v 42 [13%]; Table 3).

**DISCUSSION**

An improvement in the pharmacotherapy of advanced HCC remains a clinical need. To our knowledge, this pivotal head-to-head comparison study is the first to demonstrate

![Graph A](image1.png)

![Graph B](image2.png)

![Graph C](image3.png)

**FIG 2.** Kaplan-Meier analysis of OS in the (A) FAS and (B) ITT populations, and (C) Kaplan-Meier analysis of PFS in the FAS. FAS, full analysis set; HR, hazard ratio; ITT, intention-to-treat; OS, overall survival; PFS, progression-free survival.
noninferiority and superiority of a monotherapy, donafenib, with statistically significant extension in OS over sorafenib for first-line treatment of advanced HCC. The favorable OS benefit of donafenib was consistent across almost all prespecified subgroups. Donafenib also showed trend of improvement in PFS, TTP, ORR, and DCR, although statistical significance was not achieved. Additionally, donafenib exhibited a better safety and tolerability profile.

As far as we know, this remains the largest phase III clinical trial in Chinese patients with HCC. The inclusion criteria were identical to those of the pivotal worldwide (SHARP) and Asia-Pacific trials of sorafenib, allowing for fair comparisons. Patients enrolled in this study were representative of the HCC population in China: ≥ 90% HBV-positive, relatively poor performance status and liver function, high AFP levels, and a higher proportion of patients with BCLC stage C. Compared with international trials, patients in this study presented with more severe baseline disease states, further emphasizing the positive response observed with donafenib.

Donafenib, a deuterated sorafenib derivative, shows increased stability with reduced susceptibility to hepatic drug-metabolizing enzymes, which may result in greater plasma exposure and reduced toxic metabolites. This improved pharmacokinetic profile of donafenib potentially explains the improved short-term efficacy and safety profile of donafenib over sorafenib, the combination of which may allow patients to obtain superior long-term survival benefit.

In vivo pharmacokinetic studies have indicated that donafenib levels in plasma and tumor tissues were higher than those of sorafenib at the same dose levels (unpublished data). Concordantly, donafenib exhibited stronger antitumor effects in human HCC xenografts compared with sorafenib (unpublished data). Clinically, the steady-state plasma concentration of donafenib (0.2 g twice a day) in Chinese patients with solid tumors, including advanced HCC, was higher (44.0-46.7 h·µg/mL), compared with 29.5-36.7 h·µg/mL for sorafenib (0.4 g twice a day) in east Asian patients. The higher donafenib exposure potentially contributed to the improvement in short-term efficacy observed with donafenib in this study.

Donafenib also exhibited a better safety and tolerability profile than sorafenib, consistent with early clinical studies of donafenib. A lower frequency of grade ≥ 3 AEs with donafenib contributed to improved patient adherence and decreased levels of drug interruption and discontinuation.

### TABLE 2. Tumor Response Evaluated by IRC and Survival Rate (FAS)

| Parameter                          | Donafenib (n = 328) | Sorafenib (n = 331) | P      |
|-----------------------------------|---------------------|---------------------|--------|
| Best overall response             | CR                  | PR                  | SD     | PD     | NE     | Confirmed DCR | Confirmed ORR | Week 24 DCR | Survival rate, % | 6 months | 9 months | 12 months | 18 months |
|                                   | 1 (0.3)             | 19 (5.8)            | 163 (49.7) | 122 (37.2) | 23 (7.0) | 101 (30.8) | 15 (4.6)       | 68 (20.7) | 52 (15.7) | 73.5             | 62.2     | 50.6     | 35.4     |
|                                   | 0                   | 12 (3.6)            | 166 (50.2) | 124 (37.5) | 29 (8.8) | 95 (28.7) | 9 (2.7)        | NA        | NA        | NA                |
|                                   |                     |                     |         |         |        |          |               |           |           |                  |

NOTE. Data are No. (%) unless otherwise indicated.

### TABLE 3. Summary of AEs (safety analysis set)

| AEs                              | Donafenib (n = 333), No. (%) | Sorafenib (n = 332), No. (%) | P       |
|----------------------------------|-----------------------------|-------------------------------|---------|
| Any AE                           | 332 (100)                   | 329 (99)                      | .3731   |
| Treatment-emergent AE            | 332 (100)                   | 329 (99)                      | .3731   |
| Drug-related AE                  | 314 (94)                    | 321 (97)                      | .1902   |
| AE of grade ≥ 3                  | 191 (57)                    | 224 (67)                      | .0082   |
| Drug-related AE of grade ≥ 3     | 125 (38)                    | 165 (50)                      | .0018   |
| SAE                              | 55 (17)                     | 67 (20)                       | .2307   |
| Drug-related SAE                 | 23 (7)                      | 22 (7)                        | 1.0000  |
| AE leading to dose interruption and reduction | 101 (30)                  | 141 (42)                      | .0013   |
| Drug-related AE leading to dose interruption and reduction | 84 (25)                    | 120 (36)                      | .0025   |
| AE leading to treatment discontinuation | 34 (10)                     | 42 (13)                       | .3324   |
| Drug-related AE leading to treatment discontinuation | 19 (6)                     | 25 (8)                        | .3544   |
| AE that resulted in death         | 6 (2)                       | 12 (4)                        | .1610   |

Abbreviations: AE, adverse event; SAE, serious adverse event.
Table 4. Drug-Related AEs of Incidence ≥ 10% (safety analysis set)

| AE                                | Donafenib (n = 333), No. (%) | Sorafenib (n = 332), No. (%) |
|-----------------------------------|-------------------------------|------------------------------|
|                                   | All Grade ≥ 3                 | All Grade ≥ 3                |
| Hand-foot skin reactions          | 168 (50) 19 (6)               | 222 (67) 41 (12)             |
| Diarrhea                          | 99 (30) 6 (2)                 | 157 (47) 11 (3)              |
| Decreased platelet count          | 93 (28) 13 (4)                | 91 (27) 5 (2)                |
| Hypertension                      | 87 (26) 30 (9)                | 93 (28) 29 (9)               |
| Elevated AST                      | 78 (23) 8 (2)                 | 90 (27) 16 (5)               |
| Alopecia                          | 74 (22) 0                     | 111 (33) 0                   |
| Rash                              | 68 (20) 1 (< 1)               | 88 (27) 7 (2)                |
| Proteinuria                       | 68 (20) 2 (1)                 | 58 (17) 1 (< 1)              |
| Elevated blood bilirubin          | 63 (19) 4 (1)                 | 66 (20) 6 (2)                |
| Hypophosphatemia                  | 56 (17) 11 (3)                | 62 (19) 15 (5)               |
| Elevated ALT                      | 52 (16) 6 (2)                 | 70 (21) 9 (3)                |
| Protein urine present             | 52 (16) 2 (1)                 | 65 (20) 2 (1)                |
| Fatigue                           | 46 (14) 0                     | 60 (18) 2 (1)                |
| Decreased WBC count               | 44 (13) 5 (2)                 | 48 (14) 4 (1)                |
| Decreased appetite                | 40 (12) 1 (< 1)               | 46 (14) 3 (1)                |
| Weight loss                       | 35 (11) 0                     | 36 (11) 1 (< 1)              |

Abbreviation: AE, adverse event.

The mass balance and biotransformation study using 14C-donafenib (unpublished data) indicated that the proportions of potentially toxic metabolites in stool and urine samples were lower than those previously reported for sorafenib, possibly explaining the improved safety profile of donafenib.

Besides showing superiority in OS compared with sorafenib, donafenib demonstrated improvements in PFS and ORR, although improvements in these secondary end points did not reach statistical significance. The survival benefit of donafenib over sorafenib was more apparent in the longer term, likely attributed to not only encouraging response and disease control but also improved tolerability. The superior long-term OS benefit with donafenib over sorafenib was supported by the subgroup analyses on the basis of the different later-line treatments that the patients received; patients who received first-line donafenib potentially continued to show a trend of survival benefits compared with those who received first-line sorafenib, regardless of whether they received later-line systemic treatment or the type received. With favorable efficacy and safety, donafenib monotherapy is a promising alternative in the first-line treatment of advanced HCC, supported by the recent recommendation from the Chinese Society of Clinical Oncology.

Nevertheless, recent research suggests favorable outcomes for immune checkpoint inhibitors combined with anti-angiogenesis therapy for HCC treatment. On the basis of the recent IMbrave150 trial, which showed that atezolizumab plus bevacizumab significantly improved OS (HR, 0.58) and PFS (HR, 0.59) compared with sorafenib, this combination has recently been approved as a first-line treatment for patients with advanced HCC. However, immune checkpoint inhibitors as a monotherapy have not achieved superior efficacy over sorafenib in HCC trials. In context, donafenib remains the sole monotherapy to show superior OS outcomes versus sorafenib. Moreover, the patients recruited in the IMbrave150 study generally had a better baseline status and the study had stricter exclusion criteria for patients with comorbidities, such as autoimmune disease, immune deficiency, severe hypertension, hemorrhagic tendency, or coinfection with HBV and HCV. Donafenib may provide a potential better option for these patients who are not suitable to receive immune checkpoint inhibitors and/or bevacizumab. In addition, trials exploring the safety and efficacy of donafenib in combination with immune checkpoint inhibitors are ongoing (ClinicalTrials.gov identifier: NCT04472858, NCT04503902, and NCT04612712).

This trial adopted an open-label design. Nevertheless, potential biases on outcome analyses have been minimized with OS as the primary end point, blinded assessment by the IRC, and data monitoring by IDMC. Furthermore, as sorafenib is an approved drug with considerable real-world evidence, our observation that more patients in the sorafenib arm continued study treatment after PD may be due to bias. Besides, response to sorafenib was known to be affected by the etiologies of HCC, as patients from China (predominantly HBV-positive) were exclusively enrolled in this trial, additional studies are required to evaluate the efficacy and safety of donafenib compared with sorafenib in non-HBV or western populations. Finally, most patients enrolled in this study were of Child-Pugh Class A, and the efficacy and safety of donafenib in the Child-Pugh Class B population need further validation.

In summary, donafenib is the first monotherapy agent to achieve superior OS results over sorafenib in patients with unresectable or metastatic HCC and presented improved safety and tolerability, rendering it a new option for the first-line treatment of advanced HCC.

**AFFILIATIONS**

1. Cancer Centre of Bayi Hospital, Nanjing Chinese Medicine University, Nanjing, China
2. Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China
3. Department of Medical Oncology, The Second Hospital of Anhui Medical University, Hefei, China
4. Department of Interventional Radiology, Hunan Cancer Hospital of Central South University, Changsha, China
5. Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China
1. Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424, 2018
2. Chen W, Zheng R, Baade PD, et al: Cancer statistics in China, 2015. CA Cancer J Clin 66:115-132, 2016
3. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182-236, 2018
4. Yang JD, Roberts LR: Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 7:448-458, 2010
5. Fan JH, Wang JB, Jiang Y, et al: Attributable causes of liver cancer mortality and incidence in China. Asian Pac J Cancer Prev 14:7251-7256, 2013
6. Yang JD, Roberts LR: Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 7:448-458, 2010

CORRESPONDING AUTHOR
Feng Bi, MD, West China Hospital, Sichuan University, No 37, Guoxue Rd, Chengdu, Sichuan Province 610041, China; e-mail: bifeng@scu.edu.cn.

EQUAL CONTRIBUTION
S.Q. and F.B. are joint first authors.

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424, 2018
2. Chen W, Zheng R, Baade PD, et al: Cancer statistics in China, 2015. CA Cancer J Clin 66:115-132, 2016
3. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182-236, 2018
4. Yang JD, Roberts LR: Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 7:448-458, 2010
5. Fan JH, Wang JB, Jiang Y, et al: Attributable causes of liver cancer mortality and incidence in China. Asian Pac J Cancer Prev 14:7251-7256, 2013
6. Yang JD, Hainaut P, Gores GJ, et al: A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16:589-604, 2019
First-Line Donafenib Versus Sorafenib in Patients With HCC

7. Qin S, Bai Y, Lim HY, et al: Randomized, multcenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 31:3501-3508, 2013
8. Chinese Society of Clinical Oncology (CSCO): Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (ed 2020). Beijing, China, 2020
9. Li X, Qiu M, Wang S, et al: A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours. Cancer Chemother Pharmacol 85:593-604, 2020
10. Roche: Investor Update, 2020. https://www.roche.com/investors/updates/inv-update-2020-02-07.html
11. Cai nap C, Qin S, Huang WT, et al: Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. J Clin Oncol 33:172-179, 2015
12. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, 2009
13. Cheng AL, Kang YK, Lin DY, et al: Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. J Clin Oncol 31:4067-4075, 2013
14. Johnson PJ, Qin S, Park JW, et al: Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J Clin Oncol 31:3517-3524, 2013
15. Kudo M, Finn RS, Qin S, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 391:1163-1173, 2018
16. Llovet JM, Montal R, Villanueva A: Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. J Hepatol 70:1262-1277, 2019
17. Yau T, Park JW, Finn RS, et al: CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol 30:2, 2019
18. Zhu AX, Rosmorduc O, Evans TR, et al: SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 33:559-566, 2015
19. Finn RS, Qin S, Ikeda M, et al: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894-1905, 2020
20. Ren Z, Zhu K, Kang H, et al: Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 33:894-900, 2015
21. Bi F, Qiu M, Chai X, et al: A multicenter phase II study of donafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 35, 2017 (suppl; abstr e15682)
22. Qin S: Primary liver cancer diagnosis and treatment expert panel of the Chinese Ministry of Health: Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition). Chin Clin Oncol 1:10, 2012
23. Bruix J, Sherman M: American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: An update. Hepatology 53:1020-1022, 2011
24. Llovet JM, Ricci S, Mazzaferro V: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
25. Bruix J, da Fonseca LG, Reig M: Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 16:617-630, 2019
26. Russak EM, Bednarczyk RE: Impact of deuterium substitution on the pharmacokinetics of pharmaceuticals. Ann Pharmacother 53:211-216, 2019
27. Furuse J, Ishii H, Nakachi K, et al: Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99:159-165, 2008
28. Minami H, Kawada K, Ebi H, et al: Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 99:1492-1498, 2008
29. US Food and Drug Administration: Center for Drug Evaluation and Research Approval Package for: Application Number NDA 21-923; Clinical Pharmacology and Biopharmaceutics Review. Nexavar, 2005
30. Marisi G, Cucchetti A, Ulixe P, et al: Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? World J Gastroenterol 24:4152-4163, 2018
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/fwc or ascopubs.org/jco/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Zhenggang Ren
Consulting or Advisory Role: AstraZeneca, Roche, Merck Sharp & Dohme

Liqing Wu
Employment: Suzhou Zelgen Biopharmaceuticals Co, Ltd.
Stock and other ownership interests: Suzhou Zelgen Biopharmaceuticals Co, Ltd.

No other potential conflicts of interest were reported.
APPENDIX

![Graph showing Kaplan-Meier analysis of OS (PPS).](image)

**FIG A1.** Kaplan-Meier analysis of OS (PPS). HR, hazard ratio; OS, overall survival; PPS, per-protocol set.
| Subgroup                                                                 | HR (95% CI)            |
|-------------------------------------------------------------------------|------------------------|
| Overall                                                                  | 0.834 (0.702 to 0.991) |
| AFP at baseline, µg/L                                                   |                        |
| ≤ 400                                                                   | 0.774 (0.593 to 1.010) |
| ≥ 400                                                                   | 0.852 (0.680 to 1.069) |
| Prior locoregional therapy                                              |                        |
| Yes                                                                     | 0.381 (0.725 to 1.070) |
| No                                                                      | 0.618 (0.421 to 0.908) |
| BCLC staging                                                            |                        |
| Stage B                                                                 | 0.806 (0.344 to 1.067) |
| Stage C                                                                 | 0.832 (0.693 to 0.998) |
| Macroscopic portal vein invasion and/or extrahepatic spread            |                        |
| Present                                                                 | 0.857 (0.704 to 1.043) |
| Absent                                                                  | 0.655 (0.451 to 0.953) |
| Etiology                                                                |                        |
| HBV                                                                     | 0.860 (0.709 to 1.019) |
| Others                                                                  | 1.121 (0.638 to 2.339) |
| Post-treatment immune checkpoint inhibitor                               |                        |
| Yes                                                                     | 0.824 (0.476 to 1.429) |
| No                                                                      | 0.827 (0.690 to 0.992) |
| Post-treatment tyrosine kinase inhibitor                                |                        |
| Yes                                                                     | 0.753 (0.522 to 1.086) |
| No                                                                      | 0.906 (0.745 to 1.101) |
| Post-treatment systemic chemotherapy                                    |                        |
| Yes                                                                     | 0.904 (0.496 to 1.649) |
| No                                                                      | 0.810 (0.677 to 0.971) |

**FIG A2.** Forest plot of HRs for OS on the basis of subgroups. AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HR, hazard ratio; OS, overall survival.

| Median TTP (95% CI), months | HR (95% CI); P |
|-----------------------------|----------------|
| Donafenib                   | 3.7 (3.6 to 3.7); 0.931 (0.777 to 1.117); .1029 |
| Sorafenib                   | 3.7 (3.5 to 3.7) |

**FIG A3.** Kaplan-Meier analysis of TTP (FAS). FAS, full analysis set; HR, hazard ratio; TTP, time to progression.

© 2021 by American Society of Clinical Oncology
**TABLE A1.** Full List of Study Investigators

| Investigator | Affiliation |
|--------------|-------------|
| Shukui Qin   | Bayi Hospital, Nanjing Chinese Medicine University, Nanjing, China |
| Feng Bi      | West China Hospital, Sichuan University, Chengdu, China |
| Shanzhi Gu   | Hunan Cancer Hospital of Central South University, Changsha, China |
| Yuxian Bai   | Harbin Medical University Cancer Hospital, Harbin, China |
| Zhendong Chen| The Second Hospital of Anhui Medical University, Hefei, China |
| Zishu Wang   | The First Affiliated Hospital of Bengbu Medical College, Bengbu, China |
| Jieer Ying   | Zhejiang Cancer Hospital, Hangzhou, China |
| Yinying Lu   | The Fifth Medical Center of PLA General Hospital, Beijing, China |
| Zhiqiang Meng| Fudan University Shanghai Cancer Center, Shanghai, China |
| Hongming Pan | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China |
| Ping Yang    | The Sixth Medical Center of PLA General Hospital, Beijing, China |
| Helong Zhang | Tangdu Hospital, Air Force Medical University, Xi’an, China |
| Xi Chen      | The 900th Hospital of PLA Joint Service Support Force, Fuzhou, China |
| Aibing Xu    | Nantong Tumor Hospital, Nantong, China |
| Chengxu Cui  | Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China |
| Bo Zhu       | Xinqiao Hospital, Army Medical University, Chongqing, China |
| Jian Wu      | The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China |
| Xiaoli Xin   | The Sixth People’s Hospital of Shenyang, Shenyang, China |
| Jufeng Wang  | Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China |
| Jinlu Shan   | Daping Hospital, Army Medical University, Chongqing, China |
| Junhui Chen  | Peking University Shenzhen Hospital, Shenzhen, China |
| Zhendong Zheng| General Hospital of Northern Theater Command, Shenyang, China |
| Li Xu        | Sun Yat-sen University Cancer Center, Guangzhou, China |
| Xiaoyu Wen   | The First Hospital of Jilin University, Changchun, China |
| Zhenyu You   | Heping Branch, General Hospital of Northern Theater Command, Shenyang, China |
| Zhenggang Ren| Zhongshan Hospital, Fudan University, Shanghai, China |
| Jianming Xu  | The Fifth Medical Center of PLA General Hospital, Beijing, China |
| Chengyou Du  | The First Affiliated Hospital of Chongqing Medical University, Chongqing, China |
| Qingxia Fan  | The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China |
| Longzhen Zhang| The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China |
| Min Tao      | The First Affiliated Hospital of Soochow University, Suzhou, China |
| Da Jiang     | The Fourth Hospital of Hebei Medical University, Shijiazhuang, China |
| Senming Wang | Zhuijiang Hospital of Southern Medical University, Guangzhou, China |
| Yongping Chen| The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China |
| Jifang Sheng | The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China |
| Xuelong Zhuang| Cancer Hospital of Shantou University Medical College, Shantou, China |
| Jun Wu       | The First People’s Hospital of Changzhou, Changzhou, China |